What’s the current market cap for Nurix Therapeutics stock?

Nurix Therapeutics (NRIX) has a market cap of $1.8bn as of June 17, 2026.

What is the P/E ratio for Nurix Therapeutics stock?

The price to earnings (P/E) ratio for Nurix Therapeutics (NRIX) stock is 0 as of June 17, 2026.

Does Nurix Therapeutics stock pay dividends?

No, Nurix Therapeutics (NRIX) stock does not pay dividends to its shareholders as of June 17, 2026.

When is the next Nurix Therapeutics dividend payment date?

Nurix Therapeutics (NRIX) stock does not pay dividends to its shareholders.

What is the beta indicator for Nurix Therapeutics?

Nurix Therapeutics (NRIX) has a beta rating of 1.98. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Nurix Therapeutics stock | $NRIX Share Price

About Nurix Therapeutics

Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.

Ticker

$NRIX

Sector

Health

Primary listing

NASDAQ

Employees

317

Headquarters

Brisbane, United States

Website

www.nurixtx.com

NRIX Metrics

BasicAdvanced

$1.8bn

-

-$3.17

1.98

-

What the Analysts think about NRIX

Analyst ratings (Buy, Hold, Sell) for Nurix Therapeutics stock.

Bulls say / Bears say

Global collaboration with Roche provides $700 million upfront and up to $2.3 billion in milestone payments, de-risking Nurix’s lead BTK degrader program and validating its targeted protein degradation platform. (Reuters)

Updated Phase 1a/1b data for NX-5948 show an 83.0% objective response rate in heavily pretreated CLL/SLL patients, a median progression-free survival of 22.1 months, and a 92.9% ORR in an earlier-line BTKi-treated cohort, highlighting robust efficacy and durability. (Reuters)

Cash, cash equivalents, and marketable securities totaled $540.7 million as of February 28, 2026, providing ample runway to advance multiple clinical programs and reducing near-term financing risk. (Reuters)

Net loss widened to $87.2 million in Q1 FY2026, compared to $56.4 million a year earlier, reflecting a high cash burn rate that may necessitate additional financing and dilute shareholders. (Reuters)

Under the Roche collaboration, Nurix is obligated to fund 40% of development costs across multiple clinical trials, which could strain its cash reserves if programs advance or encounter setbacks. (Reuters)

Revenue declined 66% year-over-year to $6.25 million in Q1 FY2026, down from $18.5 million in the prior year period due to the end of its initial Sanofi collaboration, underscoring lumpy partnership-driven revenues. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 16 Jun 2026.

NRIX Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

NRIX Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

NRIX News

AllArticlesVideos

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

About Nurix Therapeutics

Ticker

Employees

NRIX Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about NRIX

Analyst Ratings

Bulls say / Bears say

NRIX Financial Performance

Income Statement

NRIX Earnings Performance

Earnings per share (EPS)

NRIX News

Roche Inks $2.3 Billion Deal, Sending This Small Biotech Stock Flying

This Biotech Stock Is Up 11% on $2.3 Billion Roche Deal for Blood Cancer Drug

Nurix Therapeutics Stock Pops on Roche Partnership

Buy $NRIX

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Nurix Therapeutics/$NRIX

About Nurix Therapeutics

Ticker

Employees

NRIX Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about NRIX

Analyst Ratings

Bulls say / Bears say

NRIX Financial Performance

Income Statement

NRIX Earnings Performance

Earnings per share (EPS)

NRIX News

Roche Inks $2.3 Billion Deal, Sending This Small Biotech Stock Flying

This Biotech Stock Is Up 11% on $2.3 Billion Roche Deal for Blood Cancer Drug

Nurix Therapeutics Stock Pops on Roche Partnership

Buy $NRIX

Upcoming events

No upcoming events

What’s the current market cap for Nurix Therapeutics stock?

What is the P/E ratio for Nurix Therapeutics stock?

Does Nurix Therapeutics stock pay dividends?

When is the next Nurix Therapeutics dividend payment date?

What is the beta indicator for Nurix Therapeutics?

Bulls say / Bears say